NeoGenomics Bolsters Liquid Diagnostics Portfolio By Acquiring Inivata
Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.
You may also be interested in...
The partnership with the Princess Margaret Cancer Center will support two studies of liquid biopsy testing for lung cancer.
During the second quarter of 2021, device company M&A values reached $2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.4bn.
The deal is Veracyte’s second major acquisition in cancer diagnostics in 2021 after agreeing to acquire Decipher Biosciences in March.